Calithera Biosciences
CALAPhase 2Market Cap
$1K
Focus
Biotech
CALA · Stock Price
USD 0.0010.59 (-100.00%)
Historical price data
Pipeline Snapshot
3030 drugs in pipeline
| Drug | Indication | Stage |
|---|---|---|
| TAK-228 | Renal Cell Carcinoma | Phase 2 |
| Telaglenastat + Carboplatin Chemotherapy + Pemetrexed Chemotherapy + Pembrolizum... | Non-Small Cell Lung Cancer | Phase 2 |
| TAK-659 | Diffuse Large B-cell Lymphoma | Phase 2 |
| Placebo + CB-839 + everolimus | Clear Cell Renal Cell Carcinoma | Phase 2 |
| Sapanisertib + Fulvestrant + Exemestane | Breast Cancer | Phase 2 |
Company Info
TypePublic
LocationUnited States
StagePhase 2
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile